FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for ...
PDS Biotechnology Corporation (NASDAQ: PDSB) announced an exclusive global license agreement with Merck KGaA (OTC: MKGAF) (OTC: MKKGY) for the tumor-targeting IL-12 fusion protein M9241 (formerly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback